-
Electronic (PDF)
-
Site License
-
Enterprisewide
PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis
GlobalData, November 2012, Pages: 70
PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis
Summary
GlobalData has released its new Country report, “PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.
The Chinese influenza vaccine market is estimated to be valued at $172m in 2012. Market growth is projected to be driven by the increase of China’s elderly population and the growth of its indigenous influenza vaccine production capacity. The barriers to the growth of China’s influenza vaccine market include the absence of national vaccination reimbursement program and the country’s focus on pandemic/avian influenza.
Scope
- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the China seasonal influenza market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in China.
1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Influenza Vaccination Policy
4.2 China
4.2.1 Influenza Vaccination Recommendations and Policies
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 FluMist
5.3.2 Afluria
5.3.3 Vaxigrip/Mutagrip
5.3.4 Influvac
5.3.5 Agrippal
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Higher level of patient awareness
6.2.2 Increased efficacy in the elderly and young children (<2 years old)
6.2.3 Improved vaccine side-effect profiles
6.2.4 More efficient vaccine manufacturing process
6.2.5 More cost-effective vaccines
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Expanded breadth of protection against viral strains
6.4.2 Increased duration of protection
6.4.3 T-cell involvement
7 Pipeline Assessment
7.1 Overview
8 Market Outlook
8.1 China
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Vaccine Coverage
9.4.2 Vaccines Included
9.4.3 Key Launch Dates
9.4.4 Influenza Vaccine Tender System Assumptions
9.4.5 General Pricing Assumptions
9.4.6 Individual Vaccine Assumptions
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About Us
9.9 Contact Us
9.10 Disclaimer
1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Leading Influenza Vaccines, 2012
Table 5: Product Profile - FluMist
Table 6: FluMist SWOT Analysis, 2012
Table 7: Product Profile - Afluria
Table 8: Afluria SWOT Analysis, 2012
Table 9: Product Profile - Vaxigrip
Table 10: Laboratory-Confirmed Influenza Infection Rates in Vaccine or Placebo Recipients and their Household Contacts
Table 11: Vaxigrip SWOT Analysis, 2012
Table 12: Product Profile - Influvac
Table 13: Influvac SWOT Analysis, 2012
Table 14: Product Profile - Agrippal
Table 15: Agrippal SWOT Analysis, 2012
Table 16: Overall Unmet Needs - Current Level of Attainment
Table 17: Clinical Unmet Needs - Gap Analysis, 2012
Table 18: Sales Forecasts ($m) for Influenza Vaccines in China, 2012-2022
Table 19: Key Events Impacting Sales of Influenza Vaccines in China, 2012
Table 20: Influenza Vaccine Market - Drivers and Barriers, 2012
Table 21: Epidemiology and Market Forecast Chinese Influenza Vaccination Rates (%), 2012-2022
Table 22: Key Launch Dates
Table 23: Physicians Surveyed, By Country
1.2 List of Figures
Figure 1: Influenza Virus Structure
Figure 2: Sales for Influenza Vaccine in China by Route of administration, 2012-2022
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
